Novartis has agreed to buy Myricx Bio, a small British oncology company, for up to $1.5bn, adding an early-stage but potentially significant technology to a cancer pipeline the industry keeps racing to expand. The Swiss group will pay $1.1bn upfront, with up to $400m more tied to milestones, in a deal that fits the pattern […]<br /> This story continues at The Next Web [...]
The Food and Drug Administration has approved a new device called the Teal Wand, which its creator describes as an "at-home vaginal sample self-collection device for cervical cancer screening.&qu [...]
Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the r [...]
Drug discovery is notoriously inefficient. Pharmaceutical projects span years, moving from one specialized human team to the next through disconnected workflows that result in knowledge loss during ea [...]
Higgsfield AI did not exist before March 2025. Fifteen months on, the video startup is in talks to raise money at a $5bn valuation, four times its worth at the start of the year. The company is seekin [...]
The chatbot era may have just received its obituary. Peter Steinberger, the creator of OpenClaw — the open-source AI agent that took the developer world by storm over the past month, raising concern [...]
The weeklong speedrunning marathon Awesome Games Done Quick 2025 wrapped up in the wee hours of Sunday morning, and organizers say it managed to pull in a total of $2,556,305 for Prevent Cancer Founda [...]